Corpus Intelligence IC Memo — MEDSTAR HARBOR HOSPITAL 2026-04-26 09:35 UTC
IC Memo — MEDSTAR HARBOR HOSPITAL
Investment Committee Memorandum | MD | 142 beds | Grade C | EBITDA uplift $13.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MEDSTAR HARBOR HOSPITAL

CCN 210034 | BALTIMORE CITY, MD | 142 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MEDSTAR HARBOR HOSPITAL is a 142-bed suburban community hospital in BALTIMORE CITY, MD with $178.3M in net patient revenue and a -13.3% operating margin. The hospital serves a payer mix of 32.0% Medicare, 16.3% Medicaid, and 51.8% commercial.

Thesis: Undervalued. Our ML models identify $13.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -13.3% to -6.0% (+736bps).

Net Revenue HCRIS$178.3M
Current EBITDA COMPUTED$-23.8M
Operating Margin COMPUTED-13.3%
Occupancy HCRIS64.4%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS82.5%
Distress Probability ML53.9%

2. Market Context & Competitive Position

59
MD Hospitals
-8.3%
State Median Margin
35
Comparable Hospitals

MD has 59 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of -13.3% places it below the state median. Among 35 size-comparable peers (71-284 beds), the median margin is -6.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (71-284), prioritizing same-state peers. 35 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MEDSTAR HARBOR HOSPITAL (Target)MD142$178.3M-13.3%
MERCY MEDICAL CENTERMD173$561.3M-3.3%
ST. AGNES HOSPITALMD183$506.7M-12.2%
TIDALHEALTH PENINSULA REGIONALMD230$493.4M0.8%
GREATER BALTIMORE MEDICAL CENTMD265$420.3M-48.5%
MEDSTAR UNION MEMORIAL HOSPITAMD191$409.3M-8.7%
ST. JOSEPH MEDICAL CENTERMD225$398.0M-3.2%
MERITUS MEDICAL CENTERMD265$396.2M1.5%
FREDERICK MEMORIAL HOSPITALMD279$388.7M-6.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $13.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.7M+210bp18mo
Cost to Collect4.5%2.5%$3.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.2M+122bp9mo
Clean Claim Rate88.0%96.0%$114K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.7M
Cost to Collect
$3.6M
Denial Rate Reduction
$3.5M
A/R Days Reduction
$2.2M
Clean Claim Rate
$114K
Total EBITDA Uplift$13.1M
Current EBITDA$-23.8M
+ RCM Uplift+$13.1M
Pro Forma EBITDA$-10.7M
Current Margin-13.3%
Pro Forma Margin-6.0%
WC Released (1x)$6.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-36.6M$-25.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-36.6M$-40.1M0.00x-100.0%
Bull Case9.0x11.0x$-32.9M$-8.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-32.9M$-19.2M0.00x-100.0%
Bear Case11.0x10.0x$-40.3M$-79.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-40.3M$-100.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 53.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 35 hospitals with 71-284 beds
  • Same-state prioritization (n=36)
  • Comp margins: P25=-12.1% / P50=-6.7% / P75=-1.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.